...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Upcoming CVOT results

Seems like CREDENCE trial results were just presented at the ISN World Congress of Nephrology in Melbourne and published in NEJM. Canagliflozin SGLT2 inhibitor in diabetics with CKD. Impressive results. Also nice write up by John Carroll in Endpoints News. Looking forward to the CKD sub-study of BETonMACE to potentially steal the spotlight by impressing even more.


New Message
Please login to post a reply